Skip to content

13F-HR filed by Casdin Capital, LLC

Casdin Capital, LLC filed this 13F-HR for the quarter ended 2017-06-30, filed 2017-08-14, with 35 holding rows worth $270,353,000.

Accession
0001172661-17-001658
Filed
2017-08-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2017

A holdings report, 35 entries on the cover page, a total value of $270,353,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $270,353,000 with VALUE read as thousands by filing date, 13F file number 028-17113. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
LOXO ONCOLOGY INC548862101COM360,000$28,868,000thousands by filing date
SAGE THERAPEUTICS INC78667J108COM255,000$20,308,000thousands by filing date
Foundation Medicine Inc350465100COM480,000$19,080,000thousands by filing date
BLUEPRINT MEDICINES CORP09627Y109COM275,000$13,934,000thousands by filing date
EVOLENT HEALTH INC CL A30050B101Stock520,000$13,182,000thousands by filing date
AGIOS PHARMACEUTICALS INC00847X104COM255,000$13,120,000thousands by filing date
SANGAMO THERAPEUTICS INC800677106COM1,400,000$12,320,000thousands by filing date
CLOVIS ONCOLOGY INC189464100COM130,000$12,172,000thousands by filing date
SPDR SER TR78464A870S&P BIOTECH150,000$11,577,000thousands by filing dateput
SPARK THERAPEUTICS INC84652J103COM170,000$10,156,000thousands by filing date
KITE PHARMA INC49803L109COM90,000$9,330,000thousands by filing date
ALNYLAM PHARMACEUTICALS INC COM02043Q107Stock105,000$8,375,000thousands by filing date
GENMARK DIAGNOSTICS INC372309104COM685,000$8,104,000thousands by filing date
EPIZYME INC29428V104COM520,000$7,852,000thousands by filing date
AUDENTES THERAPEUTICS INC.05070R104Common Stock400,000$7,652,000thousands by filing date
BLUEBIRD BIO INC09609G100COM65,000$6,828,000thousands by filing date
TESARO INC881569107COM48,000$6,713,000thousands by filing date
VOYAGER THERAPEUTICS INC92915B106COMMON STOCK740,000$6,630,000thousands by filing date
CODEXIS INC192005106COM1,190,000$6,486,000thousands by filing date
GLOBAL BLOOD THERAPEUTICS USD37890U108COM215,000$5,880,000thousands by filing date
ILLUMINA INC452327109COM31,500$5,466,000thousands by filing date
Gilead Sciences,Inc.375558103COM75,000$5,309,000thousands by filing date
MYOKARDIA INC62857M105COM395,000$5,175,000thousands by filing date
Gilead Sciences,Inc.375558103COM60,000$4,247,000thousands by filing datecall
SYROS PHARMACEUTICALS INC87184Q107COM182,141$2,931,000thousands by filing date
CYTOMX THERAPEUTICS INC23284F105COMMON STOCK177,500$2,751,000thousands by filing date
MYRIAD GENETICS INC62855J104COM100,000$2,584,000thousands by filing datecall
OVID THERAPEUTICS INC690469101COMMON STOCK221,700$2,326,000thousands by filing date
JOUNCE THERAPEUTICS INC481116101COM160,000$2,245,000thousands by filing date
EDITAS MEDICINE INC28106W103COM133,333$2,237,000thousands by filing date
VERADIGM INC01988P108COMMON STOCK150,000$1,914,000thousands by filing datecall
FATE THERAPEUTICS INC31189P102COM550,000$1,782,000thousands by filing date
AMYRIS INC03236M200COM NEW500,000$1,590,000thousands by filing date
PACIFIC BIOSCIENCES CALIF INC COM69404D108Stock300,000$1,068,000thousands by filing date
CURIS INC231269101COM85,000$161,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001172661-17-001658this filing2017-08-14acceptance time not in the bulk data set